

Are your **MRI contrast agents** cost-effective?

Learn more about generic **Gadolinium-Based Contrast Agents**.



**FRESENIUS
KABI**

caring for life

AJNR

Genetics of Parkinson Disease

E. Ben-David and R. Tu

AJNR Am J Neuroradiol 2015, 36 (3) 445-447

doi: <https://doi.org/10.3174/ajnr.A4092>

<http://www.ajnr.org/content/36/3/445>

This information is current as
of April 19, 2024.

Genetics of Parkinson Disease

E. Ben-David and R. Tu

ABBREVIATION: PD = Parkinson disease

Parkinson disease (PD) is a degenerative disorder of the nervous system. It is characterized by loss of dopamine-producing cells which, in time, develops into motor system dysfunction. A small portion of PD cases are purely genetic. Currently, diagnosis is based on clinical examination. Molecular imaging is most sensitive and novel techniques are promising; however, their use is largely limited to research. Anatomic imaging is not disease-specific in this disorder, though it may be used to rule out alternative diagnoses known to mimic PD.

HISTORY OF PARKINSON DISEASE

The description of tremors and other symptoms of PD is found in ancient texts.^{1,2} The eponym of the disease was bestowed posthumously, in the late 1800s, by Jean-Martin Charcot upon James Parkinson, a British apothecary and surgeon, who described “paralysis agitans” in a monograph entitled *An Essay on the Shaking Palsy* in 1817.³ PD is the second most common neurodegenerative disorder after Alzheimer disease.⁴ It is caused by impairment of the dopaminergic system, initially affecting movement. In later stages, cognition and behavior may also be affected.

Pathologically, PD is associated with dopaminergic neuronal cell loss and accumulation of Lewy bodies and Lewy neuritis within affected cells. Clinical symptoms develop when between 70%–80% of the involved nerve terminals have degenerated.⁵ Prevalence of PD is approximately 1% of the population over the age of 50.^{6,7} Its reported annual incidence rate is 13.4 per 100,000 in the general population; however, over the age of 60 years, the incidence rate greatly increases.⁸

WHAT ARE THE CLINICAL MANIFESTATIONS OF PARKINSON DISEASE?

PD is a movement disorder with a slow onset, frequently presenting initially with coordination difficulties. Later, bradykinesia, rigidity, postural instability, and resting tremors are the dominant features of the disease.⁹ The time lag between the initial symptoms and diagnosis may be several years.¹⁰

A depletion of dopaminergic production may be seen in other diseases as well. Atypical PD, also known as Parkinson Plus Syndromes, represents 15% of patients presenting with Parkinson-like symptoms. However, these syndromes (multiple system atrophy, Lewy body dementia, progressive supranuclear palsy, and corticobasal degeneration) do not respond to dopamine therapy.

ARE THERE GENETIC TYPES OF PD?

Initially, the genetic component of PD was questioned, especially in PD occurring after the age of 60.¹¹ In a large twin study examining concordance for PD in twins, no concordance was found.¹² However, additional studies found a Mendelian inheritance pattern, especially in early onset PD.^{13,14} Currently, monogenic PD is thought to cause 3%–5% of all PD.¹⁵ Detection of the genes was performed using linkage analysis and positional cloning in families suspected of having a genetic component. The genes discovered to have a link to PD were designated the “*PARK*” genes.¹⁶ The inheritance patterns may be autosomal dominant, as is seen in the *PARK1*, 3, 5, and 8 genes. Autosomal recessive PD is linked to *PARK2*, 6, and 7. A polymorphic or multiple genetic form of late onset PD has been described as well.¹⁷

THE PRION DISEASE HYPOTHESIS

In recent years, there has been an increasing body of research suggesting that α -synuclein, which accumulates in Lewy bodies in patients with PD, is a prionlike protein. The protein aggregates in a misfolded configuration and demonstrates properties of self-propagation to adjacent cells.^{18–20} The similarity of genetic forms of PD and prion diseases is stated as an argument on behalf of this hypothesis.²¹

From the Department of Radiology, George Washington University Hospital, Washington, DC.

Please address correspondence to Raymond Tu, MD, MS, FACR, Department of Radiology, George Washington University Hospital, 901 23rd St NW, Washington, DC 20037; e-mail: Raymond.Tu@progressiveradiology.net

<http://dx.doi.org/10.3174/ajnr.A4092>

IS THERE DIAGNOSTIC TESTING FOR PD?

Currently, diagnosis of Parkinson disease is based on the clinically characteristic signs of bradykinesia, rigidity, and resting tremor. Asymmetric onset of symptoms and a response to levodopa are considered supporting diagnostic features.¹⁶

WHAT IS THE ROLE OF IMAGING IN PD?

MR Imaging. The role of iron in the pathogenesis of Parkinson disease has been and continues to be investigated.^{22,23} Iron, which has ferromagnetic properties and is excessively deposited in the substantia nigra of patients with PD, led many to believe that this could potentially be an imaging marker of the disease, especially with T2/T2* imaging.^{24–26} In addition, more advanced MR imaging techniques have been evaluated, such as SWI^{27,28} and magnetic transfer imaging.^{29,30} One limitation of iron-based imaging is that it is nonspecific and may be seen in myriad normal or non-PD patients with parkinsonism.

Voxel-based morphometry uses high-resolution images for the assessment of brain structure. In a study of carriers of *PARK2* and 6 heterozygous carriers, an increase in volume of the posterior putamen and the internal globus pallidus was seen, possibly a compensatory reaction to dopaminergic dysfunction.³¹

Evaluation of white matter tracts, basal ganglia, and substantia nigra integrity using regional apparent diffusion coefficients and fractional anisotropy can be performed using DTI.^{32–35}

Resting-state MR imaging shows promise in the evaluation of abnormal neural networks, which is seen as hypersynchronicity in basal ganglia-thalamo-cortical loops.^{36,37}

High-field (7T) MRS demonstrates elevated putaminal and pontine gamma-aminobutyric acid levels.³⁸ This is promising; however, larger studies are required to validate this technique for clinical use.

Molecular Imaging. Radionuclide (¹⁸F)fluoro-L-dopa or FDOPA) uptake by dopaminergic neurons makes this molecule particularly useful as a sensitive tool for assessing the dopaminergic pathway.

In a comprehensive review, van der Veegt et al¹⁵ discussed, at length, the use of molecular as well as structural imaging in genetic forms of PD. The use of [¹⁸F]FDOPA PET and SPECT imaging is characteristic for sporadic PD but is nonspecific for genetic PD. A pattern similar to idiopathic PD of presynaptic dopaminergic dysfunction was seen in most genetic forms of PD.

CONCLUSIONS

Diagnosis of PD still rests on a characteristic clinical examination. Only a fraction of these patients will have a monogenetic etiology. Of the imaging modalities, radionuclide studies appear to be the most sensitive diagnostic tool. Structural imaging is currently noncontributory for diagnosis; however, it may be used to rule out other diseases that may have a similar clinical presentation. Genetic and idiopathic forms of PD have similar imaging appearances, suggesting a common pathophysiology.

REFERENCES

1. García Ruiz PJ. **Prehistory of Parkinson's disease** [in Spanish]. *Neurologia* 2004;19:735–37

2. Stern G. **Did parkinsonism occur before 1817?** *J Neurol Neurosurg Psychiatry* 1989;52(suppl):11–12
3. Olanow CW, Stern MB. **Parkinson's disease: unresolved issues.** *Ann Neurol* 2008;64(suppl 2):S1–2
4. Nussbaum RL, Ellis CE. **Alzheimer's disease and Parkinson's disease.** *N Engl J Med* 2003;348:1356–64
5. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. **Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.** *J Neurol Sci* 1973;20:415–55
6. de Lau LM, Breteler MM. **Epidemiology of Parkinson's disease.** *Lancet Neurol* 2006;5:525–35
7. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. **Mapping of a gene for Parkinson's disease to chromosome 4q21–q23.** *Science* 1996;274:1197–99
8. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. **Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity.** *Am J Epidemiol* 2003;157:1015–22
9. Hoehn MM, Yahr MD. **Parkinsonism: onset, progression and mortality.** *Neurology* 1967;17:427–42
10. Lees AJ, Hardy J, Revesz T. **Parkinson's disease.** *Lancet* 2009;373:2055–66
11. Tanner CM, Ottman R, Goldman SM, et al. **Parkinson disease in twins: an etiologic study.** *JAMA* 1999;281:341–46
12. Ward CD, Duvoisin RC, Ince SE, et al. **Parkinson's disease in 65 pairs of twins and in a set of quadruplets.** *Neurology* 1983;33:815–24
13. Barbeau A, Pourcher E. **New data on the genetics of Parkinson's disease.** *Can J Neurol Sci* 1982;9:53–60
14. Lazzarini AM, Myers RH, Zimmerman TR, et al. **A clinical genetic study of Parkinson's disease: evidence for dominant transmission.** *Neurology* 1994;44:499–506
15. van der Veegt JP, van Nuenen BF, Bloem BR, et al. **Imaging the impact of genes on Parkinson's disease.** *Neuroscience* 2009;164:191–204
16. Farlow J, Pankratz ND, Wojcieszek J, et al. **Parkinson disease overview.** In: Pagon RA, Adam MP, Ardinger HH, et al, eds. *GeneReviews* [Internet]. Seattle: University of Washington; 1993–2014. 2004 May 25 [updated 2014 Feb 27]
17. Hamza TH, Zabetian CP, Tenesa A, et al. **Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.** *Nat Genet* 2010;42:781–85
18. Olanow CW, Brundin P. **Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?** *Mov Disord* 2013;28:31–40
19. Hansen C, Angot E, Bergstrom A-L, et al. **α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.** *J Clin Invest* 2011;121:715–25
20. Angot E, Steiner JA, Lema Tome CM, et al. **Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo.** *PLoS One* 2012;7:e39465
21. Hilker R, Brotchie JM, Chapman J. **Pros and cons of a prion-like pathogenesis in Parkinson's disease.** *BMC Neurol* 2011;11:74
22. Gotz ME, Double K, Gerlach M, et al. **The relevance of iron in the pathogenesis of Parkinson's disease.** *Ann N Y Acad Sci* 2004;1012:193–208
23. Zecca L, Youdim MB, Riederer P, et al. **Iron, brain ageing and neurodegenerative disorders.** *Nat Rev Neurosci* 2004;5:863–73
24. Rutledge JN, Hilal SK, Silver AJ, et al. **Study of movement disorders and brain iron by MR.** *AJR Am J Roentgenol* 1987;149:365–79
25. Gorell JM, Ordidge RJ, Brown GG, et al. **Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease.** *Neurology* 1995;45:1138–43
26. Cho Z-H, Oh S-H, Kim J-M, et al. **Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging.** *Mov Disord* 2011;26:713–18
27. Ashwell GJ, Urasinska-Wojcik B, Phillips LJ. **In situ stepwise synthesis of functional multijunction molecular wires on gold electrodes and gold nanoparticles.** *Angew Chem Int Ed Engl* 2010;49:3508–12

28. Wang Y, Butros SR, Shuai X, et al. **Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging.** *AJNR Am J Neuroradiol* 2012;33:266–73
29. Michaeli S, Oz G, Sorce DJ, et al. **Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts.** *Mov Disord* 2007;22:334–40
30. Nestratil I, Michaeli S, Liimatainen T, et al. **T1rho and T2rho MRI in the evaluation of Parkinson's disease.** *J Neurol* 2010;257:964–68
31. Binkofski F, Reetz K, Gaser C, et al. **Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia.** *Neurology* 2007;69:842–50
32. Le Bihan D. **Looking into the functional architecture of the brain with diffusion MRI.** *Nat Rev Neurosci* 2003;4:469–80
33. Scherfler C, Frauscher B, Schocke M, et al. **White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study.** *Ann Neurol* 2011;69:400–07
34. Bosnell R, Giorgio A, Johansen-Berg H. **Imaging white matter diffusion changes with development and recovery from brain injury.** *Dev Neurorehabil* 2008;11:174–86
35. Schocke MFH, Seppi K, Esterhammer R, et al. **Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD.** *Neurology* 2002;58:575–80
36. Baudrexel S, Witte T, Seifried C, et al. **Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease.** *Neuroimage* 2011;55:1728–38
37. Skidmore FM, Yang M, Baxter L, et al. **Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease.** *Neuroimage* 2013;75:249–61
38. Emir UE, Tuite PJ, Oz G. **Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 Tesla proton MRS.** *PLoS One* 2012;7:e30918